Boryung, Lotus Pharma signs CDMO deal on anticancer injection
The company will provide the Taiwan-based firm's cytotoxic anticancer drugs in local market from 2026
By Dec 12, 2024 (Gmt+09:00)
LG Chem to sell water filter business to Glenwood PE for $692 million
Mirae Asset to be named Korea Post’s core real estate fund operator
KT&G eyes overseas M&A after rejecting activist fund's offer
StockX in merger talks with Naver’s online reseller Kream
Meritz backs half of ex-manager’s $210 mn hedge fund
South Korea's Boryung Corp. said on Thursday it signed a contract with Lotus Pharmaceutical, a Taiwanese oncology firm, for contract development and manufacturing organization (CDMO) to cytotoxic drugs.
Under the agreement, Boryung will manufacture an anticancer injection for Lotus.
The company plans to supply the agent to Lotus starting in 2026.
The product name will be disclosed by agreement between the two companies.
Boryung will manufacture the anticancer drug at its EU-GMP-certified plant in Yesan, South Chungcheong Province.
The facility, designed by Novo Nordisk Engineering (NNE), can produce 6 million vials annually.
Write to Ji-Hyun Lee at bluesky@hankyung.com
-
Aerospace & DefenseBoryung invests $10 million in Intuitive MachinesDec 06, 2024 (Gmt+09:00)
1 Min read -
Mergers & AcquisitionsEugene PE, KDB PE to acquire Boryung Biopharma for $231 millionJun 27, 2024 (Gmt+09:00)
2 Min read